About: Amantadine in treatment of chronic hepatitis C virus infection?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Amantadine in treatment of chronic hepatitis C virus infection? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Amantadine in treatment of chronic hepatitis C virus infection?
Creator	Lim, J Cheung, R Siegel, R Wooten, D
topic	covid:2313381a739fa3c8c9e6e50b9b50305caabcddbf#this
Source	Medline; PMC
abstract	Summary. Treatment of chronic hepatitis C (CHC) continues to be an important and growing challenge. As the response rate to FDA‐approved treatment improved over the past decade, we are facing increasing number of difficult‐to‐treat patients such as those who have failed prior anti‐viral therapy. The role of amantadine in the treatment of CHC remains unclear. Studies thus far have produced conflicting results, and type II error could not be excluded. This review summarized results published in the literature from 1997 to 2003, and reviewed the existing questions and controversies regarding the use of amantadine. Current literature suggests that amantadine is ineffective as monotherapy. Amantadine increased the sustained virologic response of certain treatment naïve patients when used in combination with interferon, and may be effective as an adjunct to interferon‐based combination therapy in some patients who have failed or relapsed on prior therapy. Factors such as small sample size, patient characteristics, and differences in treatment protocols including amantadine preparation and duration of therapy might explain the conflicting observations of various studies. Further investigations are needed to define optimal dosing and formulation of amantadine, and its appropriate role in management of CHC infection.
has issue date	2005-06-09(xsd:dateTime)
bibo:doi	10.1111/j.1365-2893.2005.00622.x
bibo:pmid	16108758
has license	no-cc
sha1sum (hex)	2313381a739fa3c8c9e6e50b9b50305caabcddbf
schema:url	https://doi.org/10.1111/j.1365-2893.2005.00622.x
resource representing a document's title	Amantadine in treatment of chronic hepatitis C virus infection?
has PubMed Central identifier	PMC7166758
has PubMed identifier	16108758
schema:publication	J Viral Hepat
resource representing a document's body	covid:2313381a739fa3c8c9e6e50b9b50305caabcddbf#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/2313381a739fa3c8c9e6e50b9b50305caabcddbf
is schema:about of	named entity 'published' named entity 'growing' named entity 'PUBLISHED' named entity 'DIFFICULT' named entity 'EXCLUDED' named entity 'MENT' named entity 'AMANTADINE' named entity 'CONTROVERSIES' named entity 'CONFLICTING' named entity 'failed' named entity 'protocols' named entity 'management' named entity 'patients' named entity 'anti-viral therapy' named entity 'prior' named entity 'adjunct' named entity 'failed' named entity 'Amantadine' named entity 'anti-viral therapy' named entity 'chronic hepatitis' named entity 'monotherapy' named entity 'Amantadine' named entity 'hepatitis C virus' named entity 'ribavirin' named entity 'current literature' named entity 'open-label trial' named entity 'ribavirin' named entity 'statistically significant' named entity 'interferon' named entity 'amantadine' named entity 'interferon-alpha' named entity 'interferon' named entity 'amantadine' named entity 'Amantadine' named entity 'interferon' named entity 'amantadine' named entity 'amantadine' named entity 'HIV' named entity 'ribavirin' named entity 'interferon' named entity 'amantadine' named entity 'interferon' named entity 'HCV' named entity 'interferon-alpha' named entity 'tolerability' named entity 'interferon-beta' named entity 'interferon' named entity 'interferon' named entity 'amantadine' named entity 'interferon' named entity 'MEDLINE' named entity 'amantadine' named entity 'amantadine' named entity 'viral replication' named entity 'ribavirin' named entity 'interferon' named entity 'p7 protein' named entity 'ribavirin' named entity 'United States Food and Drug Administration' named entity 'monotherapy' named entity 'interferon-alpha' named entity 'genotype' named entity 'meta-analysis' named entity 'influenza' named entity 'amantadine' named entity 'observational study' named entity 'coronavirus' named entity 'ribavirin' named entity 'statistically significant' named entity 'chronic liver disease' named entity 'interferon-alpha' named entity 'ribavirin' named entity 'interferon-alpha' named entity 'randomized trials' named entity 'ribavirin' named entity 'monotherapy'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software